Keyphrases
DNA Damage Response
100%
Heat Shock Protein 90 (Hsp90)
100%
Ovarian Carcinoma Cells
100%
PARP Inhibitor (PARPi)
100%
Ganetespib
57%
High-grade Serous Ovarian Cancer (HGSOC)
42%
DNA Repair
28%
Ovarian Carcinoma
28%
Homologous Recombination
28%
DNA Damage Repair
28%
Talazoparib
28%
Non-BRCA
28%
DNA Damage
14%
Pathway Alteration
14%
Molecular Targets
14%
Cell Survival
14%
Repair Method
14%
Small Molecule Inhibitors
14%
Irradiation
14%
Cell Viability
14%
Commercially Available
14%
Ovarian Cancer Cells
14%
Breast Cancer Susceptibility Gene 1 (BRCA1)
14%
Pharmacological Inhibitors
14%
Critical DNA
14%
Clinical Perspective
14%
Targeted Inhibition
14%
Inducing Agents
14%
Mutant Cell Line
14%
Cell Cycle Checkpoint
14%
BRCA2
14%
OVCAR-3
14%
BRCAness
14%
DNA Damage Response Pathway
14%
Homologous Recombination Pathway
14%
Client Proteins
14%
Homologous Recombination Proficient
14%
Medicine and Dentistry
Krukenberg Tumor
100%
DNA Damage Response
100%
Carcinoma Cell
100%
Poly ADP Ribose Polymerase
100%
Heat Shock Protein 90
100%
DNA Repair
55%
PARP Inhibitor
55%
Homologous Recombination
44%
Ganetespib
44%
Cell Line
22%
Talazoparib
22%
DNA Damage
11%
Cell Survival
11%
Maturation
11%
Cell Viability
11%
BRCA1
11%
Client
11%
BRCA2
11%
Ovarian Carcinoma Cell Line
11%
Cell Cycle Checkpoint
11%
Cell Mutant
11%
OVCAR-3 Cell Line
11%
Biochemistry, Genetics and Molecular Biology
Heat Shock Protein
100%
DNA Damage Response
100%
Poly ADP Ribose Polymerase
100%
DNA Repair
62%
Homologous Recombination
50%
DNA Damage
12%
Maturation
12%
Cell Survival
12%
Small Molecule
12%
Cell Viability
12%
Cell Mutant
12%
BRCA1
12%
BRCA2
12%
Cell Cycle Checkpoint
12%
Pharmacology, Toxicology and Pharmaceutical Science
Ovary Carcinoma
100%
Heat Shock Protein 90
100%
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
50%
Ganetespib
40%
Talazoparib
20%
Molecular Target
10%
Cell Viability
10%